Scribe Therapeutics IPO: revenue, losses and offering terms from its S-1
Scribe Therapeutics priced its IPO at $15 a share on 27 Jul 2026 and raised $129 million. Its shares trade on Nasdaq as SCTX. Revenue was $51.2 million in 2025, up 87% from 2024, with a net loss of $21.8 million.
Headlines
- Revenue, 2025
- $51M
- Up 87% on the year before
- Net loss, 2025
- $22M
- Revenue, First quarter of 2026
- $2M
- Down 87% on a year earlier
- IPO price
- $15
- $129M raised
Scribe Therapeutics IPO terms
From the final prospectus (424B4).
- Exchange
- Nasdaq Global Market
- Ticker
- SCTX
- IPO price
- $15
- Shares offered
- 8,580,000
- Raised
- $129M
- Registered
- $123M, the amount the filing fee is paid on
- Underwriters
- Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities and Wells Fargo Securities
- First filed
- 2 Jul 2026
Scribe Therapeutics revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2024 | $27M | - | -$48M |
| 2025 | $51M | -$26M | -$22M |
| First quarter of 2025 | $17M | - | - |
| First quarter of 2026 | $2M | -$12M | -$17M |
Scribe Therapeutics share structure and company facts
- Employees
- 89
- Headquarters
- Alameda, California
Scribe Therapeutics shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $15
- Priced 27 Jul 2026
- First close
- $18.97
- +26% on the IPO price
- Latest close
- $15.60
- +4% on the IPO price
Scribe Therapeutics' IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Scribe Therapeutics' newest prospectus (424B4 filed 27 Jul 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.